ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 177 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $203,000 | -4.7% | 2,850 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $213,000 | -8.2% | 2,850 | +3.6% | 0.01% | -41.7% |
| Q2 2019 | $232,000 | -11.8% | 2,750 | 0.0% | 0.02% | -14.3% |
| Q1 2019 | $263,000 | +11.9% | 2,750 | 0.0% | 0.03% | +12.0% |
| Q3 2018 | $235,000 | -26.3% | 2,750 | 0.0% | 0.02% | -30.6% |
| Q2 2018 | $319,000 | +43.0% | 2,750 | 0.0% | 0.04% | +44.0% |
| Q1 2018 | $223,000 | – | 2,750 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 936,777 | $53,218,000 | 16.69% |
| Fairmount Funds Management LLC | 316,952 | $18,006,000 | 6.55% |
| ARMISTICE CAPITAL, LLC | 1,836,000 | $104,303,000 | 1.77% |
| Soleus Capital Management, L.P. | 182,400 | $10,362,000 | 1.62% |
| Portland Global Advisors LLC | 62,635 | $3,558,000 | 0.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 40,000 | $2,263,000 | 0.55% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $113,336,000 | 0.53% |
| Yorktown Management & Research Co Inc | 10,400 | $591,000 | 0.44% |
| Hennion & Walsh Asset Management, Inc. | 120,240 | $6,831,000 | 0.36% |
| Virtus ETF Advisers LLC | 9,599 | $545,000 | 0.24% |